Immunosuppression and PSC
Download
1 / 4

Christoph Schramm, Ansgar W. Lohse I. Medizinische Klinik und Poliklinik - PowerPoint PPT Presentation


  • 199 Views
  • Uploaded on

Immunosuppression and PSC. Christoph Schramm, Ansgar W. Lohse I. Medizinische Klinik und Poliklinik Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany. Immunosuppression and PSC - background.

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about ' Christoph Schramm, Ansgar W. Lohse I. Medizinische Klinik und Poliklinik' - stella-finch


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
Christoph schramm ansgar w lohse i medizinische klinik und poliklinik

Immunosuppression and PSC

Christoph Schramm, Ansgar W. Lohse

I. Medizinische Klinik und Poliklinik

Universitätsklinikum Hamburg-Eppendorf,

Hamburg, Germany


Immunosuppression and psc background
Immunosuppression and PSC - background

  • Up to 10 % of PSC patients have overlapping features with autoimmune hepatitis (secondary AIH)

  • Patients with features of autoimmune hepatitis benefit from immunosuppressive treatment

  • A potential benefit of immunosuppression on early stages of PSC is unknown


Hypothesis
Hypothesis

  • Patients with an inflammatory type of PSC / secondary autoimmune hepatitis benefit from immunosuppression with prednisolone/azathioprine


Study group project
Study Group project

  • Retrospective study:

    • Collect data on patients with PSC who received immunosuppression not related to IBD

    • Compare long term survival/Ltx to matched control population without immunosuppression

  • Prospective study:

    • Define criteria for immunosuppression in PSC, e.g. ALT > 3x ULN, IgG > 1,2x ULN, histology with mHAI > 6, Scheuer > 2 (portal/periportal activity)

    • Prospectively collect data